Shots:
Eli Lilly has entered into a definitive agreement to acquire AtaiBeckley, incl. its asset, BPL-003 (mebufotenin benzoate) & VLS-01 (buccal film formulation of DMT) to treat treatment-resistant depression; closing expected in Q3’26
Lilly will acquire AtaiBeckley for $6.75/share, plus a CVR of ~$2.5/share tied to development & regulatory milestones for BPL-003 & VLS-01. The…
